Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) Director William Lis sold 13,814 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.67, for a total value of $492,745.38. Following the completion of the sale, the director now directly owns 35,106 shares in the company, valued at $1,252,231.02. This represents a 28.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Zai Lab Stock Up 4.2%
Shares of ZLAB stock traded up $1.46 during trading hours on Monday, reaching $36.01. 750,956 shares of the stock traded hands, compared to its average volume of 903,528. The firm has a market capitalization of $3.97 billion, a PE ratio of -14.46 and a beta of 0.96. Zai Lab Limited Unsponsored ADR has a 1-year low of $16.01 and a 1-year high of $44.34. The business has a fifty day moving average price of $32.80 and a 200 day moving average price of $30.83.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.05. The business had revenue of $106.49 million during the quarter, compared to analysts' expectations of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. Research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.
Institutional Trading of Zai Lab
A number of hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab during the 4th quarter worth about $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd bought a new stake in Zai Lab in the first quarter worth $75,000. Barclays PLC increased its position in Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after buying an additional 2,856 shares during the last quarter. Finally, Advisors Preferred LLC bought a new position in Zai Lab during the first quarter valued at about $110,000. 41.65% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on ZLAB shares. JPMorgan Chase & Co. lifted their price target on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Bank of America restated a "neutral" rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th.
View Our Latest Analysis on ZLAB
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
